An additional limitation is the ability of DFO to induce overexpression of hypoxia-inducible factor 1α (HIF1α); a recent report by Lang et al. indicated that co-administration of DFO and the HIF1α inhibitor lificiguat synergistically impaired proliferation in pancreatic cancer cell lines [229]. Here, HIF1A is linked to pancreatic neoplasm.